WO2012115437A3 - 신규한 암 치료 표적인 ｍａｐ７ｄ２ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물 - Google Patents

신규한 암 치료 표적인 ｍａｐ７ｄ２ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물 Download PDF

Info

Publication number
WO2012115437A3
WO2012115437A3 PCT/KR2012/001316 KR2012001316W WO2012115437A3 WO 2012115437 A3 WO2012115437 A3 WO 2012115437A3 KR 2012001316 W KR2012001316 W KR 2012001316W WO 2012115437 A3 WO2012115437 A3 WO 2012115437A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
map7d2
pharmaceutical composition
protein
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/001316
Other languages
English (en)
French (fr)
Other versions
WO2012115437A2 (ko
Inventor
권기선
김선영
최소영
도소희
박성섭
이광표
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120016917A external-priority patent/KR101376599B1/ko
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2012115437A2 publication Critical patent/WO2012115437A2/ko
Publication of WO2012115437A3 publication Critical patent/WO2012115437A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 신규한 암 치료 표적인 MAP7D2 단백질의 발현 또는 활성 억제제를 유효성분으로 함유하는 암 치료 또는 암 전이 억제용 약학적 조성물에 관한 것으 로, 구체적으로 인체 암 조직의 대규모 유전자 발현 데이터베이스를 구축하여 데이 터마이닝 기법을 통해 신규한 표적화 항암 후보 표적을 발굴하였고, 이를 암 세포 주에서의 유전자 발현 양상을 바탕으로, 적절한 암 세포주를 선정하여 표적 후보 유전자의 억제를 통해 실험적 검증을 하였고, 이를 통해 MAP7D2가 신장암, 폐암, 대장암, 난소암, 위암 및 간암과 같은 다양한 암 조직 또는 암 세포에서 과발현되 고, MAP7D2의 억제에 의해 암세포의 성장, 이동, 침윤 및 전이가 저해되고 세포사 멸이 유도됨으로써, 신규한 항암제의 표적으로서 MAP7D2의 가능성을 확인하였으므 로, MAP7D2의 발현 수준을 이용하여 암을 진단하거나, MAP7D2 단백질의 발현 또는 활성 억제제를 암의 치료 또는 암전이 억제용 약학적 조성물의 유효성분으로서 유 용하게 이용할 수 있다.
PCT/KR2012/001316 2011-02-25 2012-02-21 신규한 암 치료 표적인 ｍａｐ７ｄ２ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물 Ceased WO2012115437A2 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0017247 2011-02-25
KR20110017247 2011-02-25
KR10-2012-0016917 2012-02-20
KR1020120016917A KR101376599B1 (ko) 2011-02-25 2012-02-20 신규한 암 치료 표적인 ｍａｐ７ｄ２ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물

Publications (2)

Publication Number Publication Date
WO2012115437A2 WO2012115437A2 (ko) 2012-08-30
WO2012115437A3 true WO2012115437A3 (ko) 2012-12-20

Family

ID=46721331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001316 Ceased WO2012115437A2 (ko) 2011-02-25 2012-02-21 신규한 암 치료 표적인 ｍａｐ７ｄ２ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물

Country Status (1)

Country Link
WO (1) WO2012115437A2 (ko)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292546A1 (en) * 2003-06-09 2008-11-27 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2149613A1 (en) * 2008-07-28 2010-02-03 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292546A1 (en) * 2003-06-09 2008-11-27 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2149613A1 (en) * 2008-07-28 2010-02-03 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERND HEUBECK ET AL.: "Tumor-associated antigenic pattern in squamous cell carcinomas of the head and neck - Analysed by SEREX", EUROPEAN JOURNAL OF CANCER, 2006 *
MADRIGAL ET AL.: "X-chromosome tiling path array detection of copy number variants in patients with chromosome X-linked mental retardation", BMC GENOMICS, vol. 8, no. 443, 2007 *

Also Published As

Publication number Publication date
WO2012115437A2 (ko) 2012-08-30

Similar Documents

Publication Publication Date Title
JOP20210207B1 (ar) مركبات ترابطية مستهدفة
JOP20210231A1 (ar) مركبات ترابطية مستهدفة كمركبات علاجية
IN2014MN01183A (ko)
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
SG11201408052WA (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
EA201391114A1 (ru) Способы использования alk-ингибиторов
WO2012061683A3 (en) Methods for treating cancer
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
BRPI0821145B8 (pt) uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido
WO2012064897A3 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
WO2011101634A3 (en) Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
WO2010009377A3 (en) Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases
IN2015DN01328A (ko)
MY193996A (en) Tripeptide compound, preparation method therefor, and application thereof
PH12013501665A1 (en) Cathepsin c inhibitors
WO2012115437A3 (ko) 신규한 암 치료 표적인 ｍａｐ７ｄ２ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12748989

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12748989

Country of ref document: EP

Kind code of ref document: A2